Neuroanatomic profile of polyglutamine immunoreactivity inhuntington disease brains

Journal of Neuropathology and Experimental Neurology

Volumn 68, Issue 3, 2009, Pages 250-261

  Herndon, Emily S ^a   Hladik, Christa L ^a   Shang, Ping ^a   Burns, Dennis K ^a   Raisanen, Jack ^a   White, Charles L ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

1C2; Frontotemporal Degeneration With Ubiquitinated Inclusions; Huntington Disease; Immunohistochemistry; Inclusions; Neuromelain; Polyglutamine

Indexed keywords

GLUTAMINE; HUNTINGTIN; MONOCLONAL ANTIBODY 1C2; POLYGLUTAMINE; PROTEIN ANTIBODY; TATA BINDING PROTEIN; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; MONOCLONAL ANTIBODY; PEPTIDE;

ADULT; AGED; ARTICLE; CEREBELLUM; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DENTATE NUCLEUS; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; HYPOPHYSIS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LATERAL GENICULATE BODY; LOCUS CERULEUS; MALE; MESENCEPHALON; NEOCORTEX; NEUROANATOMY; PONS; PRIORITY JOURNAL; SCHOOL CHILD; SPINAL CORD; SUBSTANTIA NIGRA; THALAMUS; BRAIN; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; BRAIN; CHILD; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; PEPTIDES;

EID: 65349177197     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/NEN.0b013e318198d320     Document Type: Article

References (28)

1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993:72;971-983
2. del Toro D, Canals JM, Gines S, et al. Mutant huntingtin impairs the post-Golgi trafficking of brain-derived neurotrophic factor but not its Val66Met polymorphism. J Neurosci 2006:26;12748-12757
3. Trottier Y, Lutz Y, Stevanin G, et al. Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias. Nature 1995:378;403-406
4. Tibben A. Genetic counselling and presymptomatic testing. In: Bates G, Harper P, Jones L, eds. Huntington's Disease. Oxford, UK: Oxford University Press, 2002:198-248
5. Jones L. The cell biology of Huntington's disease. In: Bates G, Harper P, Jones L eds. Huntington's Disease. Oxford, UK: Oxford University Press, 2002:348-386
6. DiFiglia M, Sapp E, Chase KO, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997:277;1990-1993
7. Sapp E, Schwarz C, Chase K, et al. Huntingtin localization in brains of normal and Huntington's disease patients. Ann Neurol 1997:42; 604-612
8. Becher MW, Kotzuk JA, Sharp AH, et al. Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: Correlation between the density of inclusions and IT15 CAG triplet repeat length. Neurobiol Dis 1998:4;387-397
9. Gourfinkel-An I, Cancel G, Duyckaerts C, et al. Neuronal distribution of intranuclear inclusions in Huntington's disease with adult onset. Neuroreport 1998:9;1823-1826
10. Gutekunst CA, Li SH, Yi H, et al. Nuclear and neuropil aggregates in Huntington's disease: Relationship to neuropathology. J Neurosci 1999: 19;2522-2534
11. Maat-Schieman ML, Dorsman JC, Smoor MA, et al. Distribution of inclusions in neuronal nuclei and dystrophic neurites in Huntington disease brain. J Neuropathol Exp Neurol 1999:58;129-137
12. Sieradzan KA, Mechan AO, Jones L, et al. Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein. Exp Neurol 1999:156;92-99
13. Lunkes A, Lindenberg K, Ben-Haiem L, et al. Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. Mol Cell 2002:10;259-269
14. van Roon-Mom MCW, Reid SJ, Jones AL, et al. Insoluble TATA-binding protein accumulation in Huntington's disease cortex. Mol Brain Res 2002:109;1-10
15. van Roon-Mom MCW, Hogg VM, Tippett LJ, et al. Aggregate distribution in frontal and motor cortex in Huntington's disease brain. Neuroreport 2006:17;667-670
16. Maat-Schieman M, Roos R, Losekoot M, et al. Neuronal intranuclear and neuropil inclusions for pathological assessment of Huntington's disease. Brain Pathol 2007:17;31-37
17. Schilling G, Klevytska A, Tebbenkamp A, et al. Characterization of huntingtin pathologic fragments in human Huntington disease, transgenic mice, and cell models. J Neuropathol Exp Neurol 2007:66; 313-320
18. Yamada M, Tsuji S, Takahashi H. Pathology of CAG repeat diseases. Neuropathology 2000:20;319-325
19. Rudnicki D, Pletnikova O, Vonsattel J-P, et al. A comparison of Huntington disease and Huntington diseaseYlike 2 neuropathology. J Neuropathol Exp Neurol 2008:67;366-374
20. Mackenzie IR, Butland SL, Devon RS, et al. Familial frontotemporal dementia with neuronal intranuclear inclusions is not a polyglutamine expansion disease. BMC Neurol 2006:6;1471-2377
21. Vonsattel JP, Myers RH, Stevens TJ, et al. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985: 44;559-577
22. Dorsman J, Pepers B, Langenberg D, et al. Strong aggregation and increased toxicity of polyleucine over polyglutamine stretches in mammalian cells. Hum Mol Genet 2002:11;1487-1496
23. Sugaya K, Matsubara S, Miyamoto K, et al. An aggregate-prone conformational epitope in trinucleotide repeat diseases. Neuroreport 2003:14;2331-2335
24. Double K, Zecca L, Cost P, et al. Structural characteristics of human substantia nigra neuromelanin and synthetic dopamine melanins. J Neurochem 2000:75;2583-2589
25. Butland S, Devon R, Huang Y, et al. CAG-encoded polyglutamine length polymorphism in the human genome. BMC Genomics 2007:8;126
26. Alafuzoff I, Parkkinen L, Al-Sarraj S, et al. Assessment of alphasynuclein pathology: A study of the BrainNet Europe Consortium. J Neuropathol Exp Neurol 2008:67;125-143
27. White CL III, Hladik C, Stark J, et al. Formic acid pretreatment enhances immunostaining of polyglutamine-containing inclusions in Huntington disease brains. Brain Pathol 2006:16;S55
28. Osmand AP, Berthelier V, Wetzel R. Imaging polyglutamine deposits in brain tissue. Methods Enzymol 2006:412;106-122